Total buying$00 buys
ALKS
Alkermes plc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$83.4k1 sells
Net open-market−$83.4kBuying minus selling
Active insiders3Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 09, 2026
Open-market transaction mix · 1 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 1 | 2 | $0 | $83.4k | -$83.4k |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (3)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- GJ-$83.5k
- RJ—
- WC+$0
ALKS transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
ALKSAlkermes plc. | Reed JoshuaSVP · CFO | M · exerciseDerivative securitySEC filing ↗ | UnknownView disclosure → | |
ALKSAlkermes plc. | Reed JoshuaSVP · CFO | F · withholdingSEC filing ↗ | -$163kView disclosure → | |
ALKSAlkermes plc. | Reed JoshuaSVP · CFO | M · exerciseSEC filing ↗ | UnknownView disclosure → | |
ALKSAlkermes plc. | Whitaker Anne ClemDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
ALKSAlkermes plc. | Whitaker Anne ClemDIR | A · grantDerivative securitySEC filing ↗ | $0View disclosure → | |
ALKSAlkermes plc. | Gaffin David JosephEVP · CLO · INC | S · sale10b5-1 detectedSEC filing ↗ | -$83.4kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period6transactionstxns
- A · Grants / awards · dominant2 · 33%
- M · Option exercise2 · 33%
- F · Tax withholding1 · 17%
- S · Open-market sells1 · 17%
Activity by reported role
A joint filing can contribute to multiple rolesChief financial officer3
SVP3
Director2
CLO1
EVP1
INC1
Reported Holdings After
Separated by insider, security, and ownership type
Reed JoshuaOrdinary Shares · Direct
5,095Oct 08, 2026
Gaffin David JosephOrdinary Shares · Direct
221,388Oct 02, 2026
Whitaker Anne ClemRestricted Stock Unit Award · Direct
7,239Oct 07, 2026
Whitaker Anne ClemNon Qualified Stock Option (Right to Buy) · Direct
17,998Oct 07, 2026
Reed JoshuaRestricted Stock Unit Award · Direct
27,492Oct 08, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Alkermes plc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Alkermes plc.?
Reed Joshua, Whitaker Anne Clem, Gaffin David Joseph.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Gaffin David Joseph reported a sale on Oct 02, 2026 valued at $83.4k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $83,455.02. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.